Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06854029 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

Study acronym: NOTRE
StatusNot Yet Recruiting
PhasePhase 4
Started2026-09-01
View on ClinicalTrials.gov ↗

Amendment history

2026-08-24
Study Status v4
Start date2026-07-01→2026-09-01
2026-06-03
Study Status v3
Primary completion date2029-12→2029-12-01
Completion date2030-06→2030-06-01
Start date2026-06→2026-07-01
2026-05-12
Study Status, Study Description, Study Design v2
Enrollment increased: 300 → 450 participants
Study description-13 characters
[...] tiveness of co-located LAI PrEP + XR-B to oral PrEP + SL-B. AnPatient open-labelpreference designtrial willfor randomly assign 300450 adults who are clinically indicated for both PrEP and MOUD [...]
2026-02-12
Study Status v1
Start date2025-11→2026-06
2025-02-25
Original filing
Duke University
455 trials monitored
See 53 trials at risk
The investigators plan to conduct an R61/33 hybrid type 2 implementation-effectiveness trial that includes 1) a one-year exploratory R61 phase that will enable the development of the intervention protocol needed for the R33 trial phase including concrete R61 phase milestones; 2) a four-year R33 phase that will include a concurrent implementation evaluation and a randomized control trial.
Trial Details
NCT Number NCT06854029
Lead Sponsor Duke University
Collaborators: Friends Research Institute, Inc., The Miriam Hospital, University of Arkansas, National Institute on Drug Abuse (NIDA)
Conditions HIV Infections, Opioid Use Disorder, Incarceration; Lens
Enrollment 450 participants
Start Date 2026-09-01
Primary Completion 2029-12-01 (estimated)
Study Completion 2030-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-26